Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ASPH | Q12797 | 1/20 | 0.46 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16991862 | 0.84 | KDM4E (0.56) | KLKB1NPC1KDM4EASPHKDM8 | |
| SCHEMBL18476454 | 0.76 | CYP2C9 (0.37) | ALDH1A1 | |
| SCHEMBL16856919 | 0.75 | MAPT (0.52) | NPC1KDM4EASPHKDM8VNN1 | |
| SCHEMBL31289746 | 0.73 | VNN1 (0.46) | KLKB1F2KDM4EASPHKDM8 | |
| SCHEMBL31184855 | 0.72 | THRB (0.55) | NPC1KDM4EASPHKDM8VNN1 | |
| SCHEMBL18088826 | 0.72 | VNN1 (0.45) | KLKB1F2NPC1KDM4EASPH | |
| SCHEMBL29142175 | 0.72 | NPC1 (0.47) | KLKB1F2NPC1KDM4EASPH | |
| SCHEMBL31289825 | 0.71 | PTK2 (0.43) | KLKB1F2KDM4EASPHKDM8 | |
| SCHEMBL28283742 | 0.71 | NPC1 (0.64) | NPC1CLK4MAPTEGFRPOLB | |
| SCHEMBL31184956 | 0.70 | ATR (0.52) | KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-12084414-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4309653-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Exithera Pharmaceuticals Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-116444506-A | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-3102200-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | EXITHERA PHARMACEUTICALS INC (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-108892661-B | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20220281813-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | EXITHERA PHARMACEUTICALS, INC. | 2022-09-08 | — | — | US | disclosed |
| US-11198673-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-10259785-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| CN-108892661-A | Therapeutic compounds and composition | 艾克赛特赫拉制药有限责任公司 | 2018-11-27 | — | — | CN | disclosed |
| US-20180244614-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | EXITHERA PHARMACEUTICALS, INC. | 2018-08-30 | — | — | US | disclosed |
| CN-106029064-B | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2018-08-14 | — | — | CN | disclosed |
| US-9994521-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170037003-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2017-02-09 | — | — | US | disclosed |
| EP-3102200-A2 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Exithera Pharmaceuticals Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9499532-B2 | Therapeutic compounds and compositions | eXIthera Pharmaceuticals Inc. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2015-08-13 | — | — | US | disclosed |
| WO-2015120062-A2 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037003-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | KLKB1 2/4885F2 21/4885NPC1 1058/4885 |
| US-12084414-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | KLKB1 2/4885F2 21/4885NPC1 1058/4885 |
| US-11198673-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | KLKB1 2/4885F2 21/4885NPC1 1058/4885 |
| US-20220281813-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | KLKB1 2/4885F2 21/4885NPC1 1058/4885 |
| US-10259785-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | KLKB1 2/4885F2 21/4885NPC1 1058/4885 |
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | KLKB1 2/4885F2 21/4885NPC1 1058/4885 |
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | KLKB1 2/4885F2 21/4885NPC1 1058/4885 |
| US-20180244614-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | KLKB1 2/4885F2 21/4885NPC1 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.